Public health company The US Food and Drug Administration (FDA) reported on Friday that it has issued warning letters to operators of two websites, http://www.hydroxychloroquine-online.com and http://www.pharmaboosters.com, that market unapproved COVID-19 products.
On 15 July 2020, the agency said it approved an abbreviated new drug application, or generic, for heparin sodium, which is an anti-coagulant to prevent blood clotting. It has recognized the increased demand for certain products during the COVID-19 public health emergency and remains deeply committed to facilitating access to medical products to help address critical needs of the American public.
The FDA has issued Emergency Use Authorizations to Boston Heart Diagnostics for its molecular Boston Heart COVID-19 RT-PCR Test and to to Luminex Corporation for its serology xMAP SARS-CoV-2 Multi-Antigen IgG Assay.
To date, the agency has currently authorized 184 tests under EUAs including 152 molecular tests, 30 antibody tests and two antigen tests.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling